Stem Cell Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Global Stem Cell Market Analysis

The Global Stem Cell Market size is estimated at USD 13.66 billion in 2025, and is expected to reach USD 22.21 billion by 2030, at a CAGR of 10.2% during the forecast period (2025-2030).

Increased awareness about stem cell types, growing demand for stem cell banking, growing demand for regenerative treatment options, and rising research and development initiatives to develop stem cell therapies are some of the major factors expected to drive the global market. In addition, increasing funding/grants for developing stem cell therapies is another factor projected to support the industry's expansion.

Rising awareness of stem cells and their pivotal role in advanced therapeutics, such as regenerative medicine and stem cell therapies, is significantly propelling market growth. For instance, a December 2023 article in Inflammation and Regeneration highlighted heightened public awareness regarding stem cells. The article emphasized that umbilical cord-derived stem cells are potent, ready-to-use sources for cell and gene therapies, particularly in regenerative medicine and immunotherapies. Consequently, the use of stem cells in creating advanced therapeutics is likely to significantly propel market growth.

Moreover, as chronic diseases become more prevalent, research into regenerative stem cell therapy has intensified, aiming to create effective treatments. For example, in December 2023, a team from the Mayo Clinic, in collaboration with international partners, showcased the efficacy of stem cell-based therapy for advanced heart failure. Additionally, in January 2024, researchers from UC Davis Health reported promising preclinical results for their stem cell therapy targeting Crohn’s disease. Given these advancements, the surge in stem cell therapy research is expected to drive the industry's growth rate in the coming years. In addition, adipose-derived stem cells (ADSCs) which are derived from adipose tissue, are gaining attention due to their ease of collection, ability to differentiate into multiple cell types, and lower ethical concerns compared to other stem cell sources like embryonic stem cells. However, stringent regulations and varying approval processes across different regions can slow down the research, development, and commercialization of stem cell therapies. In addition, the development, manufacturing, and clinical application of stem cell therapies can be expensive, limiting access to these treatments, which is likely to restrain the market growth.

Stem Cells Market Insights and Trends

The Human Embryonic Cell Segment is Expected to Have Significant Growth in the Market Over the Forecast Period

By product type, the human embryonic cell segment of stem cells is estimated to have a market size of USD 1.11 billion in 2024, and market forecast shows it is expected to reach USD 1.76 billion by 2029 with a CAGR of 9.58% during 2024 to 2029.

The human embryonic cell segment is expected to grow at a steady pace, driven by advances in regenerative medicine, increasing funding for stem cell research, and ongoing breakthroughs in overcoming technical and ethical hurdles.

The therapeutic applications of human embryonic cells in treating diseases like Alzheimer's, Parkinson's, spinal cord injuries, and heart disease hold substantial promise. As research progresses, more clinical trials are likely to emerge, fueling growth in this segment. For instance, as reported in an August 2023 article in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, various clinical trials are exploring the use of stem cells, including embryonic stem cells, in treating Alzheimer's disease. While these treatments are in their early stages, stem cell therapy holds considerable promise not only for Alzheimer's but also for other neurodegenerative disorders.

Similarly, according to the article published in the Tissue Engineering and Regenerative Medicine journal in March 2024, human embryonic stem cells hold immense potential in regenerative medicine, paving the way for treatments of diseases once deemed incurable. Hence, with the continued research and development of human embryonic cells for disease treatment, the segment is likely to have significant growth over the forecast period.

Therefore, the continued research and developments in human embryonic cells for various applications are expected to drive the market growth of the human embryonic cell segment of stem cells over the forecast period.

Oncology Disorders Segment is Expected to Have a Significant Stem Cells Market Share Over the Forecast Period

By application, the oncology disorders segment is estimated to witness a market size of USD 2.78 billion in 2024, which is expected to reach USD 4.58 billion by 2029 with a CAGR of 10.49% over the forecast period.

The oncology disorders segment in the stem cell market is experiencing significant growth due to the increasing application of stem cell therapies in cancer treatment, including hematological cancers (blood cancers like leukemia and lymphoma) and solid tumors (such as breast, lung, and liver cancer). Stem cell therapies are becoming a promising alternative or adjunct to traditional cancer treatments like chemotherapy and radiation.

The stem cell market segmentation includes product type, application, and treatment type. By product type, the market is segmented into adult stem cells, human embryonic cells, pluripotent stem cells, and other product types. By application, the market is segmented into neurological disorders, orthopedic treatments, oncology disorders, injuries and wounds, cardiovascular diseases, and other applications. By treatment type, the market is segmented into allogeneic stem cell therapy, auto logic stem cell therapy, and syngeneic stem cell therapy. As the stem cell market expands, diverse end users will remain pivotal in advancing, applying, and commercializing stem cell therapies across multiple medical domains. In addition, stem cell transplantation holds immense promise in treating a wide range of diseases, from blood cancers to neurodegenerative diseases.

North America is Expected to Have the Largest Growth in the Market Over the Forecast Period

By geography, the North America region is likely to hold the largest growth with an estimated market size of USD 5.95 billion in 2024, expected to reach USD 9.37 billion by 2029 with a CAGR of 9.50% over the forecast period. The North America stem cell market is expected to continue growing rapidly, driven by strong R&D investments, supportive regulatory environments, technological innovations, and the increasing demand for effective treatments for chronic diseases.

Industry analysis shows that the increase in burden of cancer in the United States is expected to fuel market growth. For instance, according to the American Cancer Society, the prevalence of mouth cancer is increasing in the country, and the country was about to report 15,490 mouth cancer cases in 2024 compared to 14,820 in 2023. Thus, the rising number of cancer cases is projected to fuel demand for advanced cancer therapies, which, in turn, will augment demand for stem cell therapies during the forecast period. In addition, a supportive regulatory framework coupled with rising demand for advanced therapeutics further fosters the regional market. For instance, in April 2023, the USFDA approved Omisirge, an allogeneic stem cell transplant therapy in the United States. Hence, the rising burden of diseases and regulatory approval of the products are expected to drive market growth in the region.

Moreover, in July 2024, Stem Cell Network initiated a national research funding competition focused on regenerative medicine. This competition aims to bolster top-tier, translational research in regenerative medicine, spanning the entire research continuum, to enhance health, social, and economic outcomes for Canadians. Therefore, the market of stem cells in the North American region is driven by substantial research funding for developing new stem cell products.

By geography, the global stem cell market research is segmented into North America (United States, Canada, Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa), and South America (Brazil, Argentina, Rest of South America). Countries like Japan, China, and South Korea are investing heavily in stem cell research and clinical trials, becoming key markets due to expanding healthcare infrastructure and increasing demand for advanced treatments.

Global Stem Cell Industry Segmentation

As per the report's scope, stem cells are biological cells that can differentiate into other types of cells. Additionally, various types of stem cells are used for therapeutic purposes. With multiple applications at the clinical stage for various diseases, these are being explored extensively by many biopharmaceutical companies in recent times. Bone marrow is a vital source of stem cells, particularly hematopoietic stem cells, which are central to the treatment of blood cancers, blood disorders, and immune system-related conditions through bone marrow transplantation.

The stem cell market segmentation includes product type, application, treatment type, and geography. By product type, the market is segmented into adult stem cells, human embryonic cells, pluripotent stem cells, and other product types. By application, the market is segmented into neurological disorders, orthopedic treatments, oncology disorders, injuries and wounds, cardiovascular disorders, and other applications. By treatment type, the market is segmented into allogeneic stem cell therapy, auto logic stem cell therapy, and syngeneic stem cell therapy. By geography, the global market is segmented into North America (United States, Canada, Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa), and South America (Brazil, Argentina, Rest of South America). The market report also covers the estimated market sizes and market trends for 17 countries across major regions globally. The report offers the market value (in USD million) for the above segments.

By Product Type
		Adult Stem Cell
		Human Embryonic Cell
		Pluripotent Stem Cell
		Other Product Types

By Application
		Neurological Disorders
		Orthopedic Treatments
		Oncology Disorders
		Injuries and Wounds
		Cardiovascular Disorders
		Other Applications

By Treatment Type
		Allogeneic Stem Cell Therapy
		Autologic Stem Cell Therapy
		Syngeneic Stem Cell Therapy

Geography
		North America United States Canada Mexico
		Europe Germany United Kingdom France Italy Spain Rest of Europe
		Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
		Middle East and Africa GCC South Africa Rest of Middle East and Africa
		South America Brazil Argentina Rest of South America